title: The effect of oral methadone on the QTc interval in advanced cancer patients: a prospective pilot study.
abstract: BACKGROUND
  Recent reports suggest that high doses of methadone may prolong QTc interval and occasionally cause torsades de pointes; however, few of these studies involved the palliative care population.
  
  
  OBJECTIVE
  The purpose of this study was to determine the effect of initiation of methadone on QTc interval in patients with cancer pain seen at the palliative care setting.
  
  
  METHODS
  We enrolled 100 patients with cancer in this prospective study. Patients were followed clinically and electrocardiographically for QTc changes at baseline, 2, 4, and 8 weeks. Contributing factors for QTc prolongation such as medications, cardiovascular diseases, and electrolytes disturbances were documented. QTc prolongation was defined as greater than 430 ms in males and greater than 450 ms in females, and significant QTc prolongation was defined as QTc interval greater than 25% increase from baseline or 500 ms or more.
  
  
  RESULTS
  Electrocardiographic (ECG) assessments were available for 100, 64, 41, and 27 patients at baseline, 2-, 4-, and 8-week follow-up, respectively. At baseline prior to initiation of methadone, 28 (28%) patients had QTc prolongation. Clinically significant increase in QTc occurred in only 1 of 64 (1.6%) patients at week 2, and none at weeks 4 and 8. There was no clinical evidence of torsades de pointes, ventricular fibrillation, or sudden death. QTc prolongation was more frequent among patients with increased baseline QTc interval.
  
  
  CONCLUSIONS
  Baseline QTc prolongation was common, whereas significant QTc interval 500 ms or more after methadone initiation rarely occurred, with no evidence of clinically significant arrhythmias. This study supports the safety of methadone use for pain control in patients with advanced cancer in the palliative care setting.
authors.affiliation: Department of Palliative Care & Rehabilitation Medicine, University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA. sreddy@mdanderson.org
authors.forename: Suresh
authors.initials: S
authors.lastname: Reddy
authors.forename: David
authors.initials: D
authors.lastname: Hui
authors.forename: Badi
authors.initials: B
authors.lastname: El Osta
authors.forename: Maxine
authors.initials: M
authors.lastname: de la Cruz
authors.forename: Paul
authors.initials: P
authors.lastname: Walker
authors.forename: J Lynn
authors.initials: JL
authors.lastname: Palmer
authors.forename: Eduardo
authors.initials: E
authors.lastname: Bruera
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000701:Analgesics, Opioid / Q000008:administration & dosage / Q000009:adverse effects* / Q000378:metabolism; D004305:Dose-Response Relationship, Drug; D004562:Electrocardiography; D005260:Female; D006801:Humans; D008133:Long QT Syndrome / Q000139:chemically induced* / Q000453:epidemiology; D008297:Male; D008691:Methadone / Q000008:administration & dosage / Q000009:adverse effects / Q000378:metabolism; D008875:Middle Aged; D009369:Neoplasms / Q000188:drug therapy*; D010146:Pain / Q000188:drug therapy; D010865:Pilot Projects; D011446:Prospective Studies
chemical_list: D000701:Analgesics, Opioid; D008691:Methadone